Literature Search

Chiba(S),Oikawa(S),Mitomi(H),Sasaki(Y),Hobo(… Curr Oncol 2026-03-21

...PMS2 and MSH6 immunohistochemistry. p53 overexpression was associated with younger patients, left-sided tumors, nodal me...

Moussa(MJ),Andreev-Drakhlin(AY),Venkatesan(A… JCO Precis Oncol 2026-03-00

...PMS2 or MLH1 in seven patients (31.8%). Germline mutation testing confirmed Lynch syndrome in 16 (67%) patients. ICI mon...

Zhao(C),Cai(C),Xie(M),Bai(B),Kuang(S),Li(D),… Front Genet None

...PMS2 dual loss pattern. A novel germline variant APC c.3799dup was identified in all affected family members but was abs...

Ni(H),Wang(X),Zhu(Y),He(C),Li(H),Deng(A),You… Front Med (Lausanne) None

...PMS2 gene (PMS2:NM_000535:exon11:c.1847T>C:p.V616A and PMS2:NM_000535:exon14:c.2444C>T:p.S815L) were considered variants...

Pragnya(C),Patil(V) Cureus 2026-03-00

...PMS2). Statistical analysis was performed to determine correlations with clinicopathological variables such as age, gend...

Al-Masri(M),Alayyan(O),Safi(Y) Sci Rep 2026-04-15

...PMS2 are more strongly associated with ILC - to varying degrees. [p < 0.001]. Additionally, ILC tumors kept several char...

Monda(SM),Oh(E),Lewicki(PJ),Kaffenberger(SD)… Eur Urol Open Sci 2026-04-00

...PMS2) and HRR (BRCA1 and BRCA2, among others) variants, comparing with an institutional cohort of MMR carriers (n = 35; ...

Dardenne(A),Loisel(C),Pellat(A),Perrier(A),M… Hered Cancer Clin Pract 2026-04-18

...PMS2 subgroups. No statistically significant differences in PFS were observed between gene groups. Performance status ≥ ...

Kawabata(R),Hara(H),Takeoka(T),Yasuhara(Y),Y… Int Cancer Conf J 2026-04-00

...PMS2 expression. Pembrolizumab combined with capecitabine and oxaliplatin (CAPOX) was initiated as fifth-line therapy, r...

Baron(J),Lagrue(E),Normand(A),Denis(MG),Duch… Pathology 2026-06-00

...PMS2). Their DOG1, MUC2, MUC5AC, MUC6, CDX2, keratin-20, and keratin-7 immunoprofiles were then compared with histopatho...